8/13/2019 Ranbaxy Final Pharma
1/12
Quick View Geography Sales Products Patents Deals R&D Guidance
8/13/2019 Ranbaxy Final Pharma
2/12
Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013
Ranbaxy LtdIndustry: Pharmaceutical
Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded
products worldwide
Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%
Category: Branded Generic, API,OTC,FTF, Unbranded Generics
Top Key Markets Top Key Product Top Key Pipeline
India
US
UK
Germany
France
Pioglitazone Hydrochloride
Atorvastatin calcium
Esomeprazole magnesium
Pioglitazone - Clinical III
Pioglitazone - Clinical II
Pioglitazone - Clinical II
Ranbaxy Generics directly competes with Branded Drugs .Product Sub-Segment Annual Sales Branded DrugsPioglitazone Hydrochloride
Atorvastatin calcium
Esomeprazole magnesium
Anti-Hypertension
Anti- Diabetes
Anti- Cholesterol
Branded Drugs (Sales)
Diovan
Actos
Lipitor
$10 Billion
$20 Billion
$30 Billion
$10 Billion
$20 Billion
$30 Billion
Ranbaxy Sales Breakup
Click on any product to know more
Therapies Contribution
Anti-Infective
CVS
Pain Mgmt.
Dermatology
34%
12.7%
12.3%
8.2%
Therapies Contribution
Anti-Infective
CVS
Pain Mgmt.
Dermatology
34%
12.7%
12.3%
8.2%
Therapies Contribution
Anti-Infective
CVS
Pain Mgmt.
Dermatology
34%
12.7%
12.3%
8.2%
YOY Gr
3%
14%
3.2%
4%
YOY Gr
3%
14%
3.2%
4%
YOY Gr
3%
14%
3.2%
4%
Recent Developments1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb
2013. 80mg was not recalled. No recall in other markets
2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US
8/13/2019 Ranbaxy Final Pharma
3/12
Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013
Ranbaxy LtdIndustry: Pharmaceutical
Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded
products worldwide
Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%
Category: Branded Generic, API,OTC,FTF, Unbranded Generics
Top Key Markets Top Key Product Top Key Pipeline
India
US
UK
Germany
France
Pioglitazone Hydrochloride
Atorvastatin calcium
Esomeprazole magnesium
Pioglitazone - Clinical III
Pioglitazone - Clinical II
Pioglitazone - Clinical II
Ranbaxy Generics directly competes with Branded Drugs .Product Sub-Segment Annual Sales Branded DrugsPioglitazone Hydrochloride
Atorvastatin calcium
Esomeprazole magnesium
Anti-Hypertension
Anti- Diabetes
Anti- Cholesterol
Branded Drugs (Sales)
Diovan
Actos
Lipitor
Recent Developments1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb
2013. 80mg was not recalled. No recall in other markets
2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US
Ranbaxy Sales Breakup YOY Gr
Anti-Infective
CVS
Pain Mgmt
Dermatology
YOY Gr
Anti-Infective
CVS
Pain Mgmt
Dermatology
8/13/2019 Ranbaxy Final Pharma
4/12
Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013
Ranbaxy LtdIndustry: Pharmaceutical
Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded
products worldwide
Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%
Category: Branded Generic, API,OTC,FTF, Unbranded Generics
Top Key Markets Top Key Product Top Key Pipeline
India
US
UK
Germany
France
Pioglitazone Hydrochloride
Atorvastatin calcium
Esomeprazole magnesium
Pioglitazone - Clinical III
Pioglitazone - Clinical II
Pioglitazone - Clinical II
Ranbaxy Top Products BreakupTherapy Product Performance MAT (Cr) YoY Gr
Pain VOLINI 126 14%
Vitamins REVITAL 132 -3.2%
Anti-Infective MOX 144 -16%
CVS STORVAS 120 32%
Anti-Infective SPORIDEX 76 14%
Anti-Infective CIFRAN 32 14%
Anti-Infective MOXCLAV 88 14%
Estimated Growth
Ranbaxy Sales BreakupYOY Gr YOY Gr
Anti-Infective
CVS
Pain Mgmt
Dermatology
Anti-Infective
CVS
Pain Mgmt
Dermatology
8/13/2019 Ranbaxy Final Pharma
5/12
Quick View Market Sales Products Patents Deals R&D Guidance
Guidance
Top line of Rs. 120 bn in 2013 which includes exclusivity for Diovan
Business grew by 10%
US
India
Other Geographies
Financial Highlights
1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb
2013. 80mg was not recalled. No recall in other markets
2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US
8/13/2019 Ranbaxy Final Pharma
6/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Geography
Ranbaxy is present in 37 different location in the world, as shown on the world map Below.
Click on any Country and see quick Snapshot about the country.
8/13/2019 Ranbaxy Final Pharma
7/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Sales
Ranbaxy is present in 37 different location in the world. The order below is by sales, select any
Market to see products sold.
India
US
UK
Germany
France
PAIN
VITAMIN TBK
CVS
AT
PTS
Therapy Product
8/13/2019 Ranbaxy Final Pharma
8/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Sales
Ranbaxy is present in 37 different location in the world. The order below is by sales, select any
Market to see products sold.
India US UK GermanyFrance
Therapy Product
PAIN
CVS
AT
PAIN
CVS
AT
PTK
8/13/2019 Ranbaxy Final Pharma
9/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Sales
Ranbaxy is present in 37 different location in the world. The order below is by sales, select any
Market to see products sold.
India US UK GermanyFrance
Therapy Product
PAIN
CVS
AT
PAIN
CVS
AT
PTK
NORMAL TABLE STRUCTRE
8/13/2019 Ranbaxy Final Pharma
10/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Patents
Ranbaxy has filed 144 Patents, 25 are in Clinical Stage II, rest are in Clinical Stage III.
PAIN CVS AT PAIN CVS AT PTK PTK PTKFiled Filed
8/13/2019 Ranbaxy Final Pharma
11/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Deals
8/13/2019 Ranbaxy Final Pharma
12/12
Quick View Geography Sales Products Patents Deals R&D Guidance
Recent Launch
Drug Name Launch Date NPV ($mn) Contribution
Nexium Anti-Infective 2013 135 34/Share Germany
Diovan Anti-Infective 2013 76 12/Share France
Valcyte Anti-Infective 2012 82 38/Share US
Atorvastatin Anti-Infective 2012 96 UK
Cravit Anti-Infective 2011 88 Germany
Atorva Anti-Infective 2010 77 US
CountryTherapy
Therapeutic Segment (Acute Therapy)
Therapeutic Segment (Chronic)
Top Related